Olvi Group's earnings call for Q4 2024 revealed continued growth, marking the ninth consecutive year of expansion. Despite this, the company's stock saw a decline of 2.88% following the announcement.

Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...